Regulatory approval of Belamaf was gained for patients with relapsed and refractory myeloma to immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies, based on results from the Phase 2 DREAMM-2 study, in which two doses of belamaf were tested (2.5 and 3.4 mg/kg) in 196 highly pretreated relapsed and refractory MM patients (median of 6–7 prior lines of therapy). This evidence concerns the gene CD38 and Miyoshi myopathy.